换肤

惠泰医疗

i问董秘

A03937

主营介绍

  • 主营业务：

    专注于电生理和血管介入医疗器械的研发、生产和销售

  • 产品类型：

    电生理、血管介入医疗器械

  • 产品名称：

    电生理 、 冠脉通路 、 外周血管介入医疗器械

  • 经营范围：

    一般经营项目是计算机软件开发与自主开发软件的销售;医疗器械产品的技术开发、咨询(不含限制项目);并提供上述产品的批发、进出口及相关配套业务(不涉及国营贸易管理商品,涉及配额、许可证管理及其他专项规定管理的商品,按国家有关规定办理申请)。,许可经营项目是III类6821医用电子仪器设备、III类6825医用高频仪器设备、III类6866医用高分子材料及制品、III类6877介入器材的生产、自产产品的销售(由分公司生产)。

主营构成分析

报告期
报告期
{"2020-06-30":{"YYSR":{"2":[["\u51a0\u8109\u901a\u8def\u7c7b","7130.62"],["\u7535\u751f\u7406","6784.81"],["OEM","2694.20"],["\u5916\u5468\u4ecb\u5165\u7c7b","2627.76"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",53.51]],"3":[["\u534e\u4e1c","5689.98"],["\u534e\u4e2d","2621.20"],["\u5883\u5916","2553.13"],["\u534e\u5357","2480.69"],["\u897f\u5357","2266.91"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",3625.47]]},"YYCB":{"2":[["\u51a0\u8109\u901a\u8def\u7c7b","2323.52"],["\u7535\u751f\u7406","1716.37"],["OEM","1080.10"],["\u5916\u5468\u4ecb\u5165\u7c7b","927.56"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",15.89]],"3":[["\u534e\u4e1c",""],["\u534e\u4e2d",""],["\u5883\u5916",""],["\u534e\u5357",""],["\u897f\u5357",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["\u51a0\u8109\u901a\u8def\u7c7b","36.34"],["\u7535\u751f\u7406","38.32"],["OEM","12.20"],["\u5916\u5468\u4ecb\u5165\u7c7b","12.85"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.28]],"3":[["\u534e\u4e1c",""],["\u534e\u4e2d",""],["\u5883\u5916",""],["\u534e\u5357",""],["\u897f\u5357",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}},"2019-12-31":{"YYSR":{"2":[["\u7535\u751f\u7406","17284.58"],["\u51a0\u8109\u901a\u8def\u7c7b","14036.47"],["OEM","5477.31"],["\u5916\u5468\u4ecb\u5165\u7c7b","3290.40"]],"3":[["\u534e\u4e1c","11726.66"],["\u534e\u4e2d","5577.89"],["\u5883\u5916","5054.94"],["\u897f\u5357","4953.14"],["\u534e\u5317","4867.73"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",7908.41]]},"YYCB":{"2":[["\u7535\u751f\u7406","3834.88"],["\u51a0\u8109\u901a\u8def\u7c7b","4752.26"],["OEM","2213.38"],["\u5916\u5468\u4ecb\u5165\u7c7b","955.85"]],"3":[["\u534e\u4e1c",""],["\u534e\u4e2d",""],["\u5883\u5916",""],["\u897f\u5357",""],["\u534e\u5317",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["\u7535\u751f\u7406","47.47"],["\u51a0\u8109\u901a\u8def\u7c7b","32.77"],["OEM","11.52"],["\u5916\u5468\u4ecb\u5165\u7c7b","8.24"]],"3":[["\u534e\u4e1c",""],["\u534e\u4e2d",""],["\u5883\u5916",""],["\u897f\u5357",""],["\u534e\u5317",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}},"2018-12-31":{"YYSR":{"2":[["\u7535\u751f\u7406","11923.97"],["\u51a0\u8109\u901a\u8def\u7c7b","7601.21"],["OEM","4357.81"]],"3":[["\u534e\u4e1c","5777.37"],["\u5883\u5916","3741.65"],["\u534e\u4e2d","3676.88"],["\u897f\u5357","3050.26"],["\u534e\u5317","2906.93"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",4729.9]]},"YYCB":{"2":[["\u7535\u751f\u7406","2811.31"],["\u51a0\u8109\u901a\u8def\u7c7b","2782.24"],["OEM","1887.03"]],"3":[["\u534e\u4e1c",""],["\u5883\u5916",""],["\u534e\u4e2d",""],["\u897f\u5357",""],["\u534e\u5317",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["\u7535\u751f\u7406","55.56"],["\u51a0\u8109\u901a\u8def\u7c7b","29.38"],["OEM","15.06"]],"3":[["\u534e\u4e1c",""],["\u5883\u5916",""],["\u534e\u4e2d",""],["\u897f\u5357",""],["\u534e\u5317",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}}}
{"YYSR":{"chartWrap2":[{"name":"\u51a0\u8109\u901a\u8def\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[7130.62,14036.47,7601.21],"columnData":[36.96,35.01,31.83],"unit":["7130.62\u4e07","1.40\u4ebf","7601.21\u4e07"]},{"name":"\u7535\u751f\u7406","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[6784.81,17284.58,11923.97],"columnData":[35.17,43.12,49.93],"unit":["6784.81\u4e07","1.73\u4ebf","1.19\u4ebf"]},{"name":"OEM","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2694.2,5477.31,4357.81],"columnData":[13.97,13.66,18.25],"unit":["2694.20\u4e07","5477.31\u4e07","4357.81\u4e07"]},{"name":"\u5916\u5468\u4ecb\u5165\u7c7b","timeData":["2020-06-30","2019-12-31"],"lineData":[2627.76,3290.4],"columnData":[13.62,8.21],"unit":["2627.76\u4e07","3290.40\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30"],"lineData":[53.51],"columnData":[0.28],"unit":["53.51\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[5689.98,11726.66,5777.37],"columnData":[29.58,29.25,24.19],"unit":["5689.98\u4e07","1.17\u4ebf","5777.37\u4e07"]},{"name":"\u534e\u4e2d","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2621.2,5577.89,3676.88],"columnData":[13.63,13.91,15.4],"unit":["2621.20\u4e07","5577.89\u4e07","3676.88\u4e07"]},{"name":"\u5883\u5916","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2553.13,5054.94,3741.65],"columnData":[13.27,12.61,15.67],"unit":["2553.13\u4e07","5054.94\u4e07","3741.65\u4e07"]},{"name":"\u534e\u5357","timeData":["2020-06-30"],"lineData":[2480.69],"columnData":[12.9],"unit":["2480.69\u4e07"]},{"name":"\u897f\u5357","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2266.91,4953.14,3050.26],"columnData":[11.78,12.36,12.77],"unit":["2266.91\u4e07","4953.14\u4e07","3050.26\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[3625.47,7908.41,4729.9],"columnData":[18.84,19.73,19.81],"unit":["3625.47\u4e07","7908.41\u4e07","4729.90\u4e07"]},{"name":"\u534e\u5317","timeData":["2019-12-31","2018-12-31"],"lineData":[4867.73,2906.93],"columnData":[12.14,12.17],"unit":["4867.73\u4e07","2906.93\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"\u51a0\u8109\u901a\u8def\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2323.52,4752.26,2782.24],"columnData":[38.32,40.42,37.19],"unit":["2323.52\u4e07","4752.26\u4e07","2782.24\u4e07"]},{"name":"\u7535\u751f\u7406","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1716.37,3834.88,2811.31],"columnData":[28.31,32.62,37.58],"unit":["1716.37\u4e07","3834.88\u4e07","2811.31\u4e07"]},{"name":"OEM","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1080.1,2213.38,1887.03],"columnData":[17.81,18.83,25.23],"unit":["1080.10\u4e07","2213.38\u4e07","1887.03\u4e07"]},{"name":"\u5916\u5468\u4ecb\u5165\u7c7b","timeData":["2020-06-30","2019-12-31"],"lineData":[927.56,955.85],"columnData":[15.3,8.13],"unit":["927.56\u4e07","955.85\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30"],"lineData":[15.89],"columnData":[0.26],"unit":["15.89\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u4e2d","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5883\u5916","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357","timeData":["2020-06-30"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u5357","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5317","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]}]},"LRBL":{"chartWrap2":[{"name":"\u51a0\u8109\u901a\u8def\u7c7b","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[36.34,32.77,29.38],"columnData":[36.34,32.77,29.38],"unit":["36.34\u4e07","32.77\u4e07","29.38\u4e07"]},{"name":"\u7535\u751f\u7406","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[38.32,47.47,55.56],"columnData":[38.32,47.47,55.56],"unit":["38.32\u4e07","47.47\u4e07","55.56\u4e07"]},{"name":"OEM","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[12.2,11.52,15.06],"columnData":[12.2,11.52,15.06],"unit":["12.20\u4e07","11.52\u4e07","15.06\u4e07"]},{"name":"\u5916\u5468\u4ecb\u5165\u7c7b","timeData":["2020-06-30","2019-12-31"],"lineData":[12.85,8.24],"columnData":[12.85,8.24],"unit":["12.85\u4e07","8.24\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30"],"lineData":[0.28],"columnData":[0.28],"unit":["2800.00"]}],"chartWrap3":[{"name":"\u534e\u4e1c","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u4e2d","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5883\u5916","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357","timeData":["2020-06-30"],"lineData":[0],"columnData":[0],"unit":["0.00"]},{"name":"\u897f\u5357","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5317","timeData":["2019-12-31","2018-12-31"],"lineData":[0,0],"columnData":[0,0],"unit":["0.00","0.00"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 冠脉通路类 7130.62万 36.96% 2323.52万 38.32% 36.34% 67.41%
电生理 6784.81万 35.17% 1716.37万 28.31% 38.32% 74.70%
OEM 2694.20万 13.97% 1080.10万 17.81% 12.20% 59.91%
外周介入类 2627.76万 13.62% 927.56万 15.30% 12.85% 64.70%
其他业务收入 53.51万 0.28% 15.89万 0.26% 0.28% 70.30%
按地区 华东 5689.98万 29.58% - - - -
华中 2621.20万 13.63% - - - -
境外 2553.13万 13.27% - - - -
华南 2480.69万 12.90% - - - -
西南 2266.91万 11.78% - - - -
华北 1920.34万 9.98% - - - -
东北 901.02万 4.68% - - - -
西北 804.11万 4.18% - - - -

董事会经营评述

　　（一）营业收入
　　1、营业收入整体情况
　　公司主营业务为电生理、冠脉通路等介入医疗器械的研发、生产与销售。报告期内，公司营业收入分别为15,317.39万元、24,177.28万元和40,396.36万元，逐年稳步增长。报告期公司主营业务收入占营业收入的比例均超过96%，主营业务突出。公司其他业务收入主要来自于材料模具销售收入、研发收入等。
　　公司主营业务收入持续增长，主要受益于公司既有业务的持续增长，以及冠脉、外周介入等新产品上市来带的增量业务收入。具体驱动因素如下：
　　（1）我国电生理和血管介入医疗器械行业持续稳定增长
　　公司主营业务的发展与我国电生理和血管介入医疗器械行业发... 查看全部▼

　　（一）营业收入
　　1、营业收入整体情况
　　公司主营业务为电生理、冠脉通路等介入医疗器械的研发、生产与销售。报告期内，公司营业收入分别为15,317.39万元、24,177.28万元和40,396.36万元，逐年稳步增长。报告期公司主营业务收入占营业收入的比例均超过96%，主营业务突出。公司其他业务收入主要来自于材料模具销售收入、研发收入等。
　　公司主营业务收入持续增长，主要受益于公司既有业务的持续增长，以及冠脉、外周介入等新产品上市来带的增量业务收入。具体驱动因素如下：
　　（1）我国电生理和血管介入医疗器械行业持续稳定增长
　　公司主营业务的发展与我国电生理和血管介入医疗器械行业发展关系密切，且行业发展受经济周期影响相对较小，稳定性较高。随着我国经济的快速发展，民众的可支配收入及医疗保健支出不断上升，人口老龄化程度提高，医保体系逐渐完善，医疗健康行业的需求将持续提升。医疗器械行业属于国家重点支持的战略新兴产业，国家出台了一系列的产业支持政策。
　　（2）新产品的上市销售是公司营业收入增长的基础
　　公司自设立以来，一直专注于电生理和冠脉通路产品的研发，经过多年的研发积累和产业化运作，公司产品陆续取得国家产品注册，产品注册获批速度和上市速度均有所加快。
　　报告期内，公司持续对产品进行升级换代、提升产品性能，并不断丰富产品种类，以满足市场需求，为公司报告期内及未来的收入持续增长奠定良好的基础。
　　（3）新市场的开拓是公司销售收入持续增长的重要保障
　　报告期内，随着公司冠脉及外周新产品的陆续上市销售及销售渠道不断拓展，公司下游经销商数量不断上升，分别为273个、438个及623个，医院覆盖数量也不断上升。截至2020年3月31日，公司产品已覆盖全国31个省、自治区和直辖市，近700家三甲医院及680余家县市级二甲医院。未来，随着公司外周产品的注册获批和陆续上市，整体产品覆盖和终端医院开拓仍会进一步上升。
　　同时，公司国际市场布局稳步推进，主要产品在全球注册数量、覆盖地区稳步上升。截至2020年3月31日，公司14个产品已完成CE注册并在欧盟各成员国内完成备案，已在韩国、巴西、加拿大、泰国、马来西亚、巴基斯坦等国家和地区完成注册，已覆盖美洲、欧盟、东亚、东南亚、中亚等发达国家市场及主要新兴市场，国际销售渠道体系逐步建立并趋于完善，销售渠道拓展保证公司业绩稳步提升。
　　2、主营业务收入产品构成分析
　　公司自设立以来一直专注于电生理设备及耗材、血管介入类医疗器械等主营业务产品的研发、生产和销售。
　　（1）电生理产品
　　报告期内，公司电生理产品收入分别为9,698.60万元、11,923.97万元和17,284.58万元，占主营业务收入比例分别为65.31%、49.93%和43.12%，年均复合增长33.50%，销售收入总额呈整体上升趋势。随着公司冠脉类业务销售额的不断提升，其占主营业务收入的比例呈整体下降趋势，但仍为公司重要的收入来源。
　　电生理产品主要包括多道电生理记录仪、电极导管、可控射频消融电极导管、房间隔穿刺系统、冷盐水灌注射频消融导管、带止血阀导管鞘等。
　　报告期内，公司电生理耗材销量的年复增长率约为24.40%，与公司营业收入增长具有一致性，产品销售实现情况与收入增长具有一致性。
　　（2）冠脉通路类产品
　　报告期内，公司冠脉通路产品销售收入分别为1,042.32万元、7,601.21万元和14,036.47万元，占主营业务收入比例分别为7.02%、31.83%和35.01%。公司冠脉通路产品主要于2016年取得医疗器械注册证，随着产品上市及对市场开拓，报告期内，公司冠脉通路产品产品销售规模增长迅速，年均复合增长率达266.97%，成为公司收入的主要来源之一。
　　冠脉通路产品主要包括亲水涂层造影导管、微导管、PTCA球囊导管、亲水涂层导丝、导引导管等。
　　报告期内，公司冠脉通路产品销量大幅上升，与产品收入增长趋势相吻合；该类产品订单订单消化能力较强，市场需求的不断提升导致产品的收入出现较大幅度增长。
　　（3）外周介入类产品
　　2019年，公司外周血管介入产品陆续上市，外周产品销售收入为3,290.40万元，占主营业务收入比例为8.21%，成为公司收入新的增长点，主要产品包括微导管和造影导管等。
　　（4）OEM产品
　　报告期内，公司OEM产品销售收入分别为4,109.86万元、4,357.81万元和5,477.31万元，占主营业务收入比重分别为27.67%、18.25%和13.66%。OEM产品整体营业收入保持上升趋势，主要得益于公司自身品牌的提升和技术的提高以及下游厂商的需求增多，但该类业务的比重呈现不断下降的趋势，主要原因系公司业务重心为自身电生理及血管介入医疗器械的研发、生产和销售，随着公司相关产品注册证的不断获批以及上市，电生理及血管介入器械收入比重不断上升，OEM业务收入占比不断下降。
　　3、主营业务收入的地域构成分析
　　医疗器械产品的销售除受市场因素影响外，受国家和地方招标政策影响较大。随着公司产品管线的扩充和中标地区不断增加，在各地区的销售均呈整体上升趋势。
　　报告期内，公司主要销售区域为华东、华中及境外，合计占比分别为55.57%、55.25%及55.77%。华东地区为我国较为发达的地区，经济发展水平、人均收入较高，医疗资源较为集中，是我国医疗器械行业重要的区域市场。公司在该地区的销售额呈快速增长趋势。
　　4、主营业务收入的季节性分析
　　报告期内，公司营业收入不存在明显的季节性波动，但由于心脑血管疾病在秋冬季发病率相对较高，心血管手术量秋冬季节较多；另外，经销商和终端医疗机构存在提前为春节备货情形，以保证自身的安全库存，以致第四季度销售金额一般略高于其他季度。 收起▲

同花顺个股页面 | F10论坛 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。